Mofegiline
Mofegiline (MDL-72974) is an orally active and blood-brain barrier-penetrant MAO-B/SSAO selective inhibitor, with an IC50 of 3.6 nM for MAO-B and 10 nM for SSAO. Mofegiline is a cationic amphiphilic compound that can induce indirect sympathomimetic effects, lysosomal accumulation, hERG channel interactions, phospholipidosis, and cell death. Mofegiline protects mice from MPTP-induced depletion of striatal dopamine, DOPAC, and HVA. Mofegiline can be used in research related to Parkinson's disease.
For research use only. We do not sell to patients.
- CAS No.: 119386-96-8
- Formula: C11H13F2N
- Molecular Weight:197.23
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
MAO-B 3.6 nM (IC50) |
MAO-A |
In Vitro
Mofegiline is a potent and selective inhibitor of rat brain mitochondrial MAO-B, with an IC50 of 3.6 nM for MAO-B and a t1/2 of 42 seconds at 50 nM[1].
Mofegiline (compound 1) is a potent dual inhibitor of SSAO (IC50 = 0.010 μM) and MAO-B (IC50 = 0.002 μM) in cell-free amine oxidase assays, with selectivity over MAO-A (IC50 = 0.75 μM) and DAO (IC50 >30 μM); it also produces phospholipidosis/cytotoxicity risk in vitro[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Mofegiline (1.25 mg/kg; i.p.; single dose; before MPTP) prevents MPTP-induced depletion of striatal dopamine, DOPAC, and HVA in mice[1].
Mofegiline (0.1-9 mg/kg; p.o.; acute or daily) does not potentiate the cardiovascular effects of intraduodenal tyramine in anesthetized rats at MAO-B selective doses acutely or chronically[1].
Mofegiline (escalating doses; i.v.) produced only minor indirect sympathomimetic cardiovascular effects in pithed rats and did not potentiate the tyramine response[1].
Mofegiline (MDL-72974) (1.25-25 mg/kg; i.p.; daily; 3 weeks) does not increase CuZn SOD activity in the striatum of male Wistar rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss-Webster (CF-W) (male, 25-30 g)[1]
-
Dosage:1.25 mg/kg
-
Administration:i.p.; once; 18 hours prior to MPTP (HY-W114750)
-
Result:Prevented MPTP-induced depletion of striatal dopamine, DOPAC, and HVA in mice.
-
Animal Model:Sprague-Dawley (male, 150-400 g)[1]
-
Dosage:1.8 mg/kg and 9 mg/kg (acute)
0.1 mg/kg or 1 mg/kg (chronic) -
Administration:p.o.; acute or daily
-
Result:Did not significantly potentiate the cardiovascular effects of intraduodenally administered tyramine in anaesthetized rats, even at 9 mg/kg acute, which was 50 times the brain MAO-B ED50 of 0.18 mg/kg.
Daily administration at 1 mg/kg, which was 40 times the brain MAO-B ED50, did not potentiate the cardiovascular effects of intraduodenally administered tyramine.
-
Animal Model:Wistar rats (Male, 200 250 g) received daily injections of either saline, 0.01 or 0.04 mg/kg Pergolide (HY-13720) or saline[3]
-
Dosage:1.25, 25 mg/kg
-
Administration:i.p.; daily; 3 weeks
-
Result:At 1.25 mg/kg, striatal CuZn SOD activity was 102%.
At 25 mg/kg, striatal CuZn SOD activity was 97%.
Had no effect on CuZn SOD at either dose.
Chemical Information
-
CAS No. 119386-96-8
-
Molecular Weight 197.23
-
Formula C11H13F2N
-
SMILES
C(C/C(=C\F)/CN)C1=CC=C(F)C=C1
-
Synonyms
MDL-72974
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)